Lens Diseases  >>  Dexycu (dexamethasone intraocular injection)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
NCT02006888: The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Completed
3
394
US
IBI-10090, Dexycu, Placebo
ICON Bioscience Inc
Inflammation, Cataracts
10/14
10/14

Download Options